Laboratory evidence has shown that cannabinoids might have a neuroprotective action. Researchers investigated whether oral dronabinol (Δ9-tetrahydrocannabinol) might slow the course of progressive multiple sclerosis. The results show that dronabinol has no overall effect on the progression of multiple sclerosis in the progressive phase.
Further reading

Leave a Reply